CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and cash equivalents		$ 9,448	$ 2,169
Restricted Cash		4	240
Clinical trial services asset	[1]	504	0
Trade receivables, net of credit losses of $212 and $192, as of June 30, 2026 and December 31, 2025, respectively		7,861	6,138
Prepaid expenses and other current assets		1,979	1,528
Inventories		6,151	5,732
Total current assets		25,947	15,807
LONG-TERM ASSETS
Restricted cash and other long-term assets		488	209
Clinical trial services asset	[1]	378	0
Operating lease right-of-use assets		2,473	1,544
Property and equipment, net		527	585
Intangible Assets		432	0
Goodwill		4,755	4,755
Total long-term assets		9,053	7,093
Total assets		35,000	22,900
CURRENT LIABILITIES
Trade payables		6,135	5,590
Employees and payroll accruals		1,591	1,442
Deferred revenues		932	920
Convertible promissory note	[2]	0	2,803
Current maturities of operating leases liability		743	425
Other current liabilities		1,758	859
Total current liabilities		11,159	12,039
LONG-TERM LIABILITIES
Convertible promissory notes, net	[3]	4,432	0
Financing liabilities		4,083	0
Deferred revenues		1,243	1,233
Non-current operating leases liability		1,813	1,159
Other long-term liabilities		54	61
Total long-term liabilities		11,625	2,453
Total liabilities		22,784	14,492
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders’ equity:
Share capital Ordinary share Authorized: 100,000,000 shares at June 30, 2026 and 75,000,000 December 31, 2025; Issued: 2,876,250 and 1,572,319 shares at June 30, 2026 and December 31, 2025, respectively; Outstanding: 2,828,362 and 1,524,431 shares as of June 30, 2026 and December 31, 2025 respectively	[4]	0	9,418
Additional paid-in capital		322,470	286,932
Treasury Shares at cost, 47,888 ordinary shares at June 30, 2026 and December 31, 2025	[4]	(3,203)	(3,203)
Accumulated deficit		(307,051)	(284,739)
Total shareholders' equity		12,216	8,408
Total liabilities and shareholders' equity		$ 35,000	$ 22,900

[1] Balance relates entirely to a related party arrangement with Oramed Pharmaceuticals Inc.

[2] Represents amounts due to Oramed Pharmaceuticals Inc. as of December 31, 2025. Oramed became a related party upon completion of the March 2026 transaction.

[3] Includes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $3,982 as of June 30, 2026.

[4] Reflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a to the condensed consolidated financial statements.